Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Articles published by Pfizer Inc.

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Pfizer Announces The Lancet Neurology Has Published Phase 3 Data for Zavegepant for the Acute Treatment of Migraine in Adults

February 16, 2023

From Pfizer Inc.

Via Business Wire

FDA Approves Pfizer's Supplemental New Drug Application for CIBINQO® (abrocitinib)

February 10, 2023

From Pfizer Inc.

Via Business Wire

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

February 09, 2023

From Pfizer Inc.

Via Business Wire

PFIZER REPORTS RECORD FULL-YEAR 2022 RESULTS AND PROVIDES FULL-YEAR 2023 FINANCIAL GUIDANCE

January 31, 2023

From Pfizer Inc.

Via Business Wire

Pfizer Expands ‘An Accord for a Healthier World’ Product Offering to Include Full Portfolio for Greater Benefit to 1.2 Billion People in 45 Lower-Income Countries

January 17, 2023

From Pfizer Inc.

Via Business Wire

U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine in Infants and Children

January 06, 2023

From Pfizer Inc.

Via Business Wire

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

January 03, 2023

From Pfizer Inc.

Via Business Wire

Pfizer Announces Positive Top-Line Results from Phase 3 Study of Hemophilia B Gene Therapy Candidate

December 29, 2022

From Pfizer Inc.

Via Business Wire

U.S. FDA Accepts for Review the Biologics License Application for Pfizer’s Investigational Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents

December 28, 2022

From Pfizer Inc.

Via Business Wire

Pfizer Announces FDA and EMA Acceptance of Etrasimod Regulatory Submissions for Ulcerative Colitis

December 21, 2022

From Pfizer Inc.

Via Business Wire

Pfizer Invites Public to View and Listen to Webcast of January 31 Conference Call with Analysts

December 20, 2022

From Pfizer Inc.

Via Business Wire

Pfizer Presents Updated Favorable Elranatamab Data from Pivotal Phase 2 MagnetisMM-3 Trial

December 10, 2022

From Pfizer Inc.

Via Business Wire

Pfizer Declares First-Quarter 2023 Dividend

December 09, 2022

From Pfizer Inc.

Via Business Wire

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years

December 08, 2022

From Pfizer Inc.

Via Business Wire

U.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer’s Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV Disease in Older Adults

December 07, 2022

From Pfizer Inc.

Via Business Wire

Pfizer and Clear Creek Bio to Collaborate on a Research Program Targeting SARS-CoV-2 Papain-Like Protease

December 06, 2022

From Pfizer Inc.

Via Business Wire

Pfizer Invites Public to Register for Webcast of Pfizer Near-Term Launches + High-Value Pipeline Day

December 01, 2022

From Pfizer Inc.

Via Business Wire

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

November 28, 2022

From Pfizer Inc.

Via Business Wire

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

November 11, 2022

From Pfizer Inc.

Via Business Wire

Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine

November 04, 2022

From Pfizer Inc.

Via Business Wire

Pfizer’s Elranatamab Granted FDA Breakthrough Therapy Designation for Relapsed or Refractory Multiple Myeloma

November 03, 2022

From Pfizer Inc.

Via Business Wire

PFIZER REPORTS STRONG THIRD-QUARTER 2022 RESULTS AND RAISES 2022 OUTLOOK

November 01, 2022

From Pfizer Inc.

Via Business Wire

Pfizer Announces Positive Top-Line Data of Phase 3 Global Maternal Immunization Trial for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate

November 01, 2022

From Pfizer Inc.

Via Business Wire

Pfizer Presents Scientific Advancements in Infectious Disease Prevention and Treatments at IDWeek 2022

October 18, 2022

From Pfizer Inc.

Via Business Wire

Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older

October 13, 2022

From Pfizer Inc.

Via Business Wire

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age

October 12, 2022

From Pfizer Inc.

Via Business Wire

Pfizer Completes Acquisition of Global Blood Therapeutics

October 05, 2022

From Pfizer Inc.

Via Business Wire

Pfizer Announces Positive Topline Results from Phase 3 TALAPRO-2 Trial

October 04, 2022

From Pfizer Inc.

Via Business Wire

Pfizer Completes Acquisition of Biohaven Pharmaceuticals

October 03, 2022

From Pfizer Inc.

Via Business Wire

Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age

September 26, 2022

From Pfizer Inc.

Via Business Wire

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.